05.04.2012 - Swedish pharma company Astra Zeneca plus Wallenberg Foundation and Swedish government pledge a record investment into the biotech industry.
Stockholm – Under a new initiative, AstraZeneca will invest €2.3m to €4.5m (SEK20m to SEK40m) a year over the next five years in early-stage research projects. The Wallenberg Foundation, a private financing institution which is dedicated to promoting scientific research and education in Sweden, will provide additional €25m (SEK220m). The money will be used to build up technology laboratories for the SciLifeLab collaboration between four Swedish universities. The contribution of the Swedish government is yet unknown, but a spokesperson already announced the government is planning a record investment in the country's life science infrastructure. The details would be published in the autumn budget. Jan Björklund, the Swedish Minister for Education, announced the SciLifeLab will become a national research institute for major research in molecular biosciences and bioinformatics. According to the government’s plan, SciLifeLab will grow to employ about 1,000 scientists and have a turnover of about €113m (SEK1bn) within a few years.SciLifeLab is a joint venture between four universities; Karolinska Institutet, the Royal Institute of Technology, Stockholm University and Uppsala University. The medical research focuses on investigating the molecular basis of complex human diseases, and seeks to find biomarkers that can help diagnose diseases and monitor their progress. The vision is to make SciLifeLab a competitive centre for high-throughput biosciences with platforms in genomics, comparative genetics, proteomics, bioimaging and functional genomics as well as research communities in biology, medicine and environmental sciences.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.